Cargando…

Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis

The highly contagious coronavirus, which had already affected more than 2 million people in 210 countries, triggered a colossal economic crisis consequently resulting from measures adopted by various goverments to limit transmission. This has placed the lives of many people infected worldwide at gre...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Meenu, Prasher, Parteek, Sharma, Mousmee, Shastri, Madhur D., Khurana, Navneet, Vyas, Manish, Dureja, Harish, Gupta, Gaurav, Anand, Krishnan, Satija, Saurabh, Chellappan, Dinesh Kumar, Dua, Kamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481067/
https://www.ncbi.nlm.nih.gov/pubmed/33254559
http://dx.doi.org/10.1016/j.mehy.2020.110254
_version_ 1783580525247594496
author Mehta, Meenu
Prasher, Parteek
Sharma, Mousmee
Shastri, Madhur D.
Khurana, Navneet
Vyas, Manish
Dureja, Harish
Gupta, Gaurav
Anand, Krishnan
Satija, Saurabh
Chellappan, Dinesh Kumar
Dua, Kamal
author_facet Mehta, Meenu
Prasher, Parteek
Sharma, Mousmee
Shastri, Madhur D.
Khurana, Navneet
Vyas, Manish
Dureja, Harish
Gupta, Gaurav
Anand, Krishnan
Satija, Saurabh
Chellappan, Dinesh Kumar
Dua, Kamal
author_sort Mehta, Meenu
collection PubMed
description The highly contagious coronavirus, which had already affected more than 2 million people in 210 countries, triggered a colossal economic crisis consequently resulting from measures adopted by various goverments to limit transmission. This has placed the lives of many people infected worldwide at great risk. Currently there are no established or validated treatments for COVID-19, that is approved worldwide. Nanocarriers may offer a wide range of applications that could be developed into risk-free approaches for successful therapeutic strategies that may lead to immunisation against the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) which is the primary causative organism that had led to the current COVID-19 pandemic. We address existing as well as emerging therapeutic and prophylactic approaches that may enable us to effectively combat this pandemic, and also may help to identify the key areas where nano-scientists can step in.
format Online
Article
Text
id pubmed-7481067
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-74810672020-09-10 Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis Mehta, Meenu Prasher, Parteek Sharma, Mousmee Shastri, Madhur D. Khurana, Navneet Vyas, Manish Dureja, Harish Gupta, Gaurav Anand, Krishnan Satija, Saurabh Chellappan, Dinesh Kumar Dua, Kamal Med Hypotheses Article The highly contagious coronavirus, which had already affected more than 2 million people in 210 countries, triggered a colossal economic crisis consequently resulting from measures adopted by various goverments to limit transmission. This has placed the lives of many people infected worldwide at great risk. Currently there are no established or validated treatments for COVID-19, that is approved worldwide. Nanocarriers may offer a wide range of applications that could be developed into risk-free approaches for successful therapeutic strategies that may lead to immunisation against the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) which is the primary causative organism that had led to the current COVID-19 pandemic. We address existing as well as emerging therapeutic and prophylactic approaches that may enable us to effectively combat this pandemic, and also may help to identify the key areas where nano-scientists can step in. Elsevier Ltd. 2020-11 2020-09-10 /pmc/articles/PMC7481067/ /pubmed/33254559 http://dx.doi.org/10.1016/j.mehy.2020.110254 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mehta, Meenu
Prasher, Parteek
Sharma, Mousmee
Shastri, Madhur D.
Khurana, Navneet
Vyas, Manish
Dureja, Harish
Gupta, Gaurav
Anand, Krishnan
Satija, Saurabh
Chellappan, Dinesh Kumar
Dua, Kamal
Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis
title Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis
title_full Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis
title_fullStr Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis
title_full_unstemmed Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis
title_short Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis
title_sort advanced drug delivery systems can assist in targeting coronavirus disease (covid-19): a hypothesis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481067/
https://www.ncbi.nlm.nih.gov/pubmed/33254559
http://dx.doi.org/10.1016/j.mehy.2020.110254
work_keys_str_mv AT mehtameenu advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis
AT prasherparteek advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis
AT sharmamousmee advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis
AT shastrimadhurd advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis
AT khurananavneet advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis
AT vyasmanish advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis
AT durejaharish advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis
AT guptagaurav advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis
AT anandkrishnan advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis
AT satijasaurabh advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis
AT chellappandineshkumar advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis
AT duakamal advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis